Misuse of drug patenting could cost the health system billions

(Medical Xpress)—Companies may be misusing the drug patenting system in order to gain control over high-cost drugs in Australia, research from the Melbourne Law School has found.

The research, published in PLOS ONE on Saturday, looked at patents on 15 high-cost or "blockbuster" drugs in Australia over the last 20 years.

It found an average of 50 patents covered each , most of which were owned by companies that did not invent the drug.

Lead author Professor Andrew Christie, Foundation Chair of Intellectual Property at Melbourne Law School, said while there was much concern about companies abusing the to keep drugs expensive, the research suggests that the blame may be being placed on the wrong party.

"It is the non-originator drug companies – those that do not develop – that are taking out the most patents. We are not sure why, but we suspect it is to ride on the coat tails of the drug's success, such as by owning an alternative formulation or delivery mechanism for the drug", he said.

With high and increasing drug costs in Australia, the potential misuse of the patenting system may come at a high cost for the health system.

"The 15 drugs in our study cost the country more than $17 billion over two decades. There are suspicions that abusive patenting by the big pharmaceutical companies is keeping that cost high."

"Our research shows that patenting by and other players may be just as important."

The team of researchers also includes Professor David Studdert of the Melbourne Law School and School of Population and and Professor Peter McIntyre of the Health Innovations Research Institute at RMIT University.

The research paper, "Patents Associated with High-Cost Drugs in Australia," can be found on the PLOS ONE website.

More information: www.plosone.org/article/info%3… journal.pone.0060812

Related Stories

Indian court to rule on generic drug industry

Jan 04, 2013

(AP)—From Africa's crowded AIDS clinics to the malarial jungles of Southeast Asia, the lives of millions of ill people in the developing world are hanging in the balance ahead of a legal ruling that will ...

High court weighs drug companies' generics policy

Mar 25, 2013

(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

Drug maker Novartis loses India patent battle (Update)

Apr 01, 2013

India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world ...

India's top court to deliver Novartis judgment

Mar 31, 2013

India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies ...

Pharmaceutical intellectual property laws need reform

Nov 07, 2011

Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation in developing new drugs, states an analysis in CMAJ (Canadian Medical Association Journal).

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments